Related Experiment Video
Updated: Jun 26, 2026
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
Conventional cytogenetics in myelofibrosis: literature review and discussion
Kebede Hussein1, Daniel L Van Dyke, Ayalew Tefferi
1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
The clinical phenotype of myelofibrosis (MF) is recognized either de novo (primary) or in the setting of polycythemia vera (post-PV) or essential thrombocythemia (post-ET). Approximately one-third of patients with primary MF (PMF) present with cytogenetic abnormalities; the most frequent are del(20q), del(13q), trisomy 8 and 9, and abnormalities of chromosome 1 including duplication 1q. Other less frequent lesions include -7/del(7q), del(5q), del(12p), +21 and der(6)t(1;6)(q21;p21.3). In general, cytogenetic abnormalities are qualitatively similar among PMF, post-ET MF and post-PV MF although their individual frequencies may differ. Based on prognostic effect, cytogenetic findings in MF are classified as either 'favorable' or 'unfavorable'. The former include normal karyotype or isolated del(20q) or del(13q) and the latter all other abnormalities. Unfavorable cytogenetic profile in both PMF and post-PV/ET MF confers an independent adverse effect on survival; it is also associated with higher JAK2V617F mutational frequency. In addition to their prognostic value, cytogenetic studies in MF ensure diagnostic exclusion of other myeloid neoplasms that are sometimes associated with bone marrow fibrosis (e.g. BCR-ABL1-positive or PDGFRB-rearranged) and also assist in specific treatment selection (e.g. lenalidomide therapy is active in MF associated with del(5q).
Insights
Cytogenetic abnormalities in myelofibrosis (MF) impact patient survival and treatment. Understanding these genetic markers is crucial for diagnosing MF and selecting appropriate therapies.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Myelofibrosis (MF) presents as primary (PMF) or secondary to polycythemia vera (post-PV) or essential thrombocythemia (post-ET).
- Cytogenetic abnormalities are present in about one-third of PMF patients, with common findings including del(20q), del(13q), trisomy 8, trisomy 9, and 1q duplication.
- These abnormalities are generally similar across MF subtypes, though their frequencies vary.
Purpose of the Study:
- To analyze the role of cytogenetic abnormalities in the diagnosis, prognosis, and treatment selection for myelofibrosis.
- To classify cytogenetic findings in MF as favorable or unfavorable based on their prognostic impact.
Main Methods:
- Review and classification of cytogenetic findings in patients with primary MF, post-ET MF, and post-PV MF.
- Correlation of cytogenetic profiles with patient survival and JAK2V617F mutational status.
- Assessment of the utility of cytogenetic studies for differential diagnosis and guiding specific therapies.
Main Results:
- Cytogenetic abnormalities in MF are classified as 'favorable' (normal karyotype, isolated del(20q), isolated del(13q)) or 'unfavorable' (all others).
- An unfavorable cytogenetic profile is linked to reduced survival in PMF and post-PV/ET MF.
- Unfavorable karyotypes are also associated with a higher frequency of the JAK2V617F mutation.
Conclusions:
- Cytogenetic analysis is vital for MF diagnosis, excluding other myeloid neoplasms, and predicting patient outcomes.
- Favorable versus unfavorable cytogenetic profiles significantly influence survival in MF patients.
- Specific chromosomal abnormalities, like del(5q), can guide targeted treatment decisions, such as lenalidomide therapy.
